Exhibit 107

Calculation of Filing Fee Tables

Form F-3

(Form Type)

Altamira Therapeutics Ltd.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount to be Registered (1)

Proposed Maximum Offering Price Per Unit (2)

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial effective date

Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Fees to Be Paid

Equity

Common shares, par value CHF 0.20 per share (3)

Other

5,855,134

$

0.7849

$

4,595,694.68

0.0001102

$

506.45

–

–

–

–

Fees Previously Paid

–

–

–

–

–

–

–

–

–

–

–

–

Carry Forward Securities

Carry Forward Securities

–

–

–

–

–

–

–

–

–

–

–

–

Total Offering Amounts

$

4,595,694.68

$

506.45

Total Fees Previously Paid

–

Total Fee Offsets

506.45

Net Fee Due

$

0

Table 2: Fee Offset Claims and Sources

Registrant or Filer Name

Form or Filing Type

File Number

Initial Filing Date

Filing Date

Fee Offset Claimed

Security Type Associated with Fee Offset Claimed

Security Title Associated with Fee Offset Claimed

Unsold Securities Associated with Fee Offset Claimed

Aggregate Offering Amount Associated with Fee Offset Claimed

Fee Paid with Fee Offset Source

Rules 457(b) and 0-11(a)(2)

Fee Offset Claims

Fee Offset Sources

Rule 457(p)

Fee Offset Claims

Altamira Therapeutics Ltd.

F-1

333-269823

02/16/2023

$

506.45

Equity

(4)

(4)

(4)

Fee Offset Sources

Altamira Therapeutics Ltd.

F-1

333-269823

03/27/2023

$

2,230.45

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminable number of additional securities that may become issuable pursuant to terms designed to prevent dilution resulting from share splits, share dividends or similar events.

(2) Estimated in accordance with Rule 457(c) under the Securities Act solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the registrant’s common shares, as reported on the NASDAQ Capital Market on May 31, 2023, a date within five business days prior to the initial filing of this registration statement on June 1, 2023.

(3) Consists of (i) up to 768,761 shares that may be acquired upon one or more conversions and/or repayments under the Convertible Loan Agreement, dated September 9, 2022, as amended on May 12, 2023, between Altamira Therapeutics Ltd. (the “Company”), FiveT Investment Management Ltd. and separate private investors, (ii) 3,413,706 common shares that may be acquired upon one or more conversions and/or amortizations under the Convertible Loan Agreement, dated May 1, 2023, by and between the Company and FiveT Investment Management Ltd. (the “Convertible Loan Agreement”), (iii) up to 1,625,487 common shares that may be acquired upon the exercise of certain warrants issued in connection with the Convertible Loan Agreement and (iv) up to 47,180 common shares that may be acquired upon the exercise of certain warrants issued in connection with the two loan agreements the Company entered into with two separate private investors on December 28, 2022.

(4) The registrant previously paid a filing fee of $2,230.45 in connection with the registration of up to an aggregate of $20,240,000 of common shares, par value CHF 0.20 per share (the “Common Shares”), Common Shares underlying pre-funded warrants and Common Shares underlying common warrants under the registrant’s registration statement on Form F-1 (File No. 333-269823) (the “Prior Registration Statement”). The registration fee shown on the table above is offset by $506.45 in fees that the registrant is entitled to offset under Rule 457(p) of the Securities Act, which the registrant previously paid with respect to unsold shares under the Prior Registration Statement. The registrant has withdrawn the Prior Registration Statement.